On November 10, the 24th Shanghai International Biotechnology and Pharmaceutical Symposium (BIO-FORUM), part of the China Biotechnology and Pharmaceutical Innovation Forum, convened in Shanghai. During this event, the “2022 China Biomedical Science and Technology Innovation Value Ranking” was unveiled. This comprehensive ranking encompasses nine distinct selection programs, spanning a wide spectrum of the biomedical landscape:
As a forward-thinking and self-improvement startup in the biotech industry, META Pharmaceuticals has made significant strides with its groundbreaking research in the field of immune metabolism. Our inclusion in the Small Molecule Innovative Drug Selection Program is a testament to our commitment to innovation.
In recognition of our growth trajectory, META Pharmaceuticals has been honored as a TOP10 Small Molecule Innovative Drug Company in the China Biopharmaceutical Science and Technology Innovation Value Ranking for 2022. Our focus on bridging the gap between metabolism and immunology positions us at the forefront of therapeutic advancements for autoimmune diseases and beyond.
In the realm of small molecule innovative drugs, we find a diverse landscape that includes both Big Pharma, which undergoes transformation and innovation from traditional generic companies, and innovative firms charting an independent course through License-in strategies. These forward-thinking companies are recognized as the most influential small molecule innovative drug companies in the Top 20.
Amidst the era of small molecule innovative drug targeting, several key players stand out:
Additionally, there are numerous other excellent biopharmaceutical companies, such as Ascent Pharma, collectively representing the driving force behind China’s future innovations.
The China Medical Research Institute, an independent research organization operating behind the scenes, falls under the umbrella of Medical City Technology. As one of the rare medical investment research institutes in China, it plays a pivotal role in shaping the investment landscape within the realm of medical big health.
The China Medical Research Institute has meticulously segmented the medical and healthcare field into six major sectors, thirty-six sub-sectors, and over two hundred sub-sectors. Through systematic investment research, it has achieved in-depth insights and a comprehensive grasp of industry trends, market dimensions, competitive dynamics, and other critical elements. Furthermore, the institute has formulated quantitative evaluation standards for each segment.
Based on the latest cutting-edge findings in immuno-metabolic biological theories, META Pharmaceuticals has identified a series of novel targets involving metabolic proteases. These targets hold the promise of safely and effectively regulating immune system function. Currently, we are concurrently developing three first-in-class small molecule innovative drug pipelines, with our core pipeline, Meta-1, scheduled for clinical study filing in 2023.
Innovation serves as the driving force behind a country’s development and progress, and it embodies the very essence upon which nations rely. As a new force in China’s biopharmaceutical industry, META Pharmaceuticals remains steadfast in its commitment to small molecule innovative drug research. We will persistently embrace innovation and development, striving to provide enhanced therapeutic options for patients across a broader range of indications, including those with autoimmune diseases.
